



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket Nos. 71369.172 and PFI-024US)

RECEIVED
OCT 01 2002
TECH CENTER 1600
10/17/02

In re Application of: Blumenberg et al.) Examiner: To Be Assigned
Serial No. 09/659,737) Group Art Unit: 1636
Filing Date: September 11, 2000)
For: GENES AND POLYNUCLEOTIDES ASSOCIATED WITH ULTRAVIOLET RADIATION-
MEDIATED SKIN DAMAGE AND USES THEREOF

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8 (a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date: 9/26/02

Rochelle Capobianco
Rochelle Capobianco

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith the references on the attached form PTO-1449, copies of which are enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97 (b) before the mailing date of the first Office Action, therefore no fee is believed to be due. I hereby state under 37 C.F.R. § 1.97 (e) (1) that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office (copy enclosed) on a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to the patentability of the invention, or that the listed documents are prior art. Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents constitute prior art under United States law, Applicants reserve the right to present to the Office relevant facts and law regarding the significance of such documents to the patentability of the claimed invention.


U.S. Patent Application No. 09/659,737
Supplemental Information Disclosure Statement
Page Two

It is respectfully requested that the Examiner initial and return copies of the enclosed form PTO-1449 with the next Patent Office communication.

Please charge any fees which might be due in connection with this matter to Deposit Account Number 08-0219.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,



Ann-Louise Kerner, Ph.D.

Reg. No. 33,523

Date: Sept. 26, 2002

HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)



Subt. For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

et

1

OF

1

Docket Number

71369.172

Application Number

09/659,737

Applicant

Blumenberg et al.

Filing Date

Group Art Unit

~~1636~~ 1652

Oct 4, 1994
RECEIVED
OCT 01 2002
TECH CENTER 1600/2900

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
2. n.	B13	Diener et al., "Activation of the c-Jun N-terminal Kinase Pathway by a Novel Protein Kinase Related to Human Germinal Center Kinase," Proc. Nat. Acad. Sci., USA, Vol. 94, 1997, pp 9687-9692
NO. n.	B14	Tibbles et al., "The Stress-Activated Protein Kinase Pathways," Cellular and Molecular Life Sciences, Vol. 55, 1999, pp 1230-1254

EXAMINER <u>M. Monsen</u>	DATE CONSIDERED 12/19/2002
------------------------------	-------------------------------

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.